triazoles has been researched along with quinoxalines in 91 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (3.30) | 18.7374 |
| 1990's | 15 (16.48) | 18.2507 |
| 2000's | 34 (37.36) | 29.6817 |
| 2010's | 26 (28.57) | 24.3611 |
| 2020's | 13 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Aso, T; Gao, Y; Nakatsu, K; Shimizu, M; Yamada, S | 1 |
| Cabral, R; Fukushima, S; Hakoi, K; Hasegawa, R; Hoshiya, T; Ito, N | 1 |
| Kamachi, S; Nishii, Y; Shimizu, M; Yamada, S | 1 |
| Browne, RG; Howard, HR; Koe, BK; Lebel, LA; Sarges, R; Seymour, PA | 1 |
| Brown, RE; Huang, FC; Jones, H; Kahen, R; Khandwala, A; Leibowitz, MJ; Loev, B; Musser, JH; Sonnino-Goldman, P | 1 |
| Bruns, RF; Trivedi, BK | 1 |
| Gordon, RJ; Leibowitz, M; Sonnino-Goldman, P; Wolf, PS | 1 |
| Iwasaki, Y; Shimizu, M; Yamada, S | 1 |
| Catarzi, D; Cecchi, L; Colotta, V; Filacchioni, G; Giusti, L; Lucacchini, A; Martini, C; Melani, F | 2 |
| Feuerstein, G; Jiang, ZG; Yue, TL | 1 |
| Shimizu, M; Wang, X; Yamada, S | 1 |
| Abd el-Samii, ZK; el-Feky, SA | 1 |
| el-Hawash, SA; Habib, NS | 1 |
| Catarzi, D; Cecchi, L; Colotta, V; Costagli, C; Filacchioni, G; Galli, A; Varano, F | 1 |
| Harada, K; Ishikawa, N; Kondo, F; Nagata, A; Oshikata, M; Shimada, T; Shimizu, M; Suzuki, M; Yamada, S | 1 |
| Matuszczak, B; Müller, CE; Pekala, E | 1 |
| Catarzi, D; Cecchi, L; Colotta, V; Filacchioni, G; Lucacchini, A; Martini, C; Trincavelli, L; Varano, F | 1 |
| Carlà, V; Catarzi, D; Cecchi, L; Colotta, V; Costagli, C; Filacchioni, G; Galli, A; Varano, F | 1 |
| Jacobson, KL; Ott, SM; Singh, JC; Watson, EL | 1 |
| Nasr, MN | 1 |
| Abouzid, KA; Badran, MM; Hussein, MH | 1 |
| Calabri, FR; Carlà, V; Catarzi, D; Colotta, V; Costagli, C; Filacchioni, G; Galli, A; Varano, F | 1 |
| Catarzi, D; Colotta, V; Filacchioni, G; Lucacchini, A; Martini, C; Trincavelli, L; Varano, F | 2 |
| Cory-Slechta, DA; Reeves, R; Thiruchelvam, M | 1 |
| Calabri, FR; Catarzi, D; Colotta, V; Deflorian, F; Filacchioni, G; Lenzi, O; Martini, C; Moro, S; Trincavelli, L; Varano, F | 1 |
| Fernández, ML; Fraga, S; Franco, JM; Paz, B; Riobó, P | 1 |
| Bier, D; Holschbach, MH; Olsson, RA; Schüller, M; Sihver, W; Wutz, W | 1 |
| Elmedal, B; Mulvany, MJ; Simonsen, U | 1 |
| Asplund Persson, A; Bengtsson, T; Grenegård, M; Lindström, E; Whiss, PA; Zalavary, S | 1 |
| Elmedal Laursen, B; Mulvany, MJ; Simonsen, U | 1 |
| Dick, HB; Krummenauer, F; Marx-Gross, S; Pfeiffer, N | 1 |
| Connell, BJ; Cribb, AE; Legge, C; Saleh, TM | 1 |
| Grenegård, M; Gunnarsson, P; Lindström, E; Persson, AA | 1 |
| Catarzi, D; Colotta, V; Filacchioni, G; Lenzi, O; Martini, C; Montopoli, C; Moro, S; Trincavelli, L; Varano, F | 1 |
| Catarzi, D; Ciampi, O; Colotta, V; Filacchioni, G; Lenzi, O; Marighetti, F; Martini, C; Morizzo, E; Moro, S; Trincavelli, L; Varani, K; Varano, F | 1 |
| Collu, G; Corona, P; La Colla, P; Loddo, R; Loriga, M; Paglietti, G; Sanna, G; Vitale, G | 1 |
| El-Hawash, SA; Habib, NS; Kassem, MA | 1 |
| Kamikawa, Y; Kojima, S; Ohno, Y; Sasaki, K; Sunagawa, M; Uchida, K | 1 |
| Gilbert, M; Laustsen, G; Wimett, L | 1 |
| Sharma, BK; Singh, P | 1 |
| Cooper, RD; Daniel-Issakani, S; Ding, R; Gururaja, TL; Huang, J; Kinoshita, T; Masuda, ES; McLaughlin, J; Payan, DG; Singh, R; Yung, S; Zhou, X | 1 |
| Borea, PA; Capelli, F; Catarzi, D; Colotta, V; Filacchioni, G; Lenzi, O; Morizzo, E; Moro, S; Varani, K; Varano, F; Vincenzi, F | 1 |
| Catarzi, D; Ciampi, O; Colotta, V; Filacchioni, G; Lenzi, O; Martini, C; Morizzo, E; Moro, S; Pedata, F; Pugliese, AM; Traini, C; Trincavelli, L; Varano, F | 1 |
| Chawla, PS; Kochar, MS | 1 |
| Benelli, U; Canovetti, A; Figus, M; Fogagnolo, P; Nardi, M | 1 |
| Chaturvedi, SC; Sharma, RN; Thakar, H; Vasu, KK | 1 |
| Kuehn, BM | 1 |
| Bojar, RA; Gawkrodger, DJ; Harris, G | 1 |
| Dieni, C; Frondaroli, A; Grassi, S; Pettorossi, VE; Scarduzio, M | 1 |
| Brown, S | 1 |
| Aldrich, CC; Shi, C | 1 |
| Carosati, E; Costi, MP; Cruciani, G; Guaitoli, G; Guerrieri, D; Ligabue, A; Luciani, R; Marverti, G; Pippi, M; Piras, S; Sforna, G | 1 |
| Grimsdale, AC; Lam, YM; Li, H; Mhaisalkar, SG; Tam, TL | 1 |
| Aggarwal, R; Kumar, V; Mittal, A; Sumran, G | 1 |
| Briddon, SJ; Hill, SJ; Kellam, B; Stoddart, LA; Vernall, AJ | 1 |
| Cai, Q; Cai, T; Ding, K; Qin, D; Yan, J; Zhou, F | 1 |
| Akinfieva, OV; Artem'eva, MM; Daliger, IL; Medvedev, OS; Medvedeva, NA; Postnikov, AB; Shevelev, SA | 1 |
| Alleyne, CH; Dhandapani, KM; King, MD | 1 |
| Badiger, S; Behnke, D; Betschart, C; Chaudhari, V; Cotesta, S; Fendt, M; Gee, CE; Hintermann, S; Hoyer, D; Jacobson, LH; Laue, G; Ofner, S; Pandit, C; Wagner, J | 1 |
| Bräuner-Osborne, H; Gajhede, M; Greenwood, JR; Hansen, KB; Kastrup, JS; Kvist, T; Mehrzad Tabrizi, F; Pickering, DS; Steffensen, TB; Traynelis, SF | 1 |
| Cooper, DP; DeLuca, HF; Finkelstein, JS; Gallagher, JC; Jones, G; Kaufmann, M; Konrad, M; Lopez, B; Maestro, M; Mourino, A; Peacock, M; Schlingmann, KP; Sigueiro, R; St-Arnaud, R | 1 |
| Fraser, K | 1 |
| Gao, AC; Gao, M; Wang, M; Zheng, QH | 1 |
| Preskorn, SH | 1 |
| Bundgaard, C; Christoffersen, CT; Jørgensen, M; Rasmussen, LK; Redrobe, JP | 1 |
| Cock, I; de Koning, CB; Giri, S; Leboho, TC; Michael, JP; Popova, I | 1 |
| Jones, G; Kaufmann, M | 1 |
| Blackwell, K; Burris, H; Campana, F; Gao, L; Gomez, P; Isakoff, S; Jiang, J; Lynn Henry, N; Macé, S; Tolaney, SM | 1 |
| Cho, Y; Furumochi, S; Fuwa, H; Konoki, K; Onoda, T; Sasaki, M; Yotsu-Yamashita, M | 1 |
| Hussar, DA | 1 |
| Cheon, JH; Kim, HS; Kim, KS; Kim, M; Yadav, DK; Yoon, S | 1 |
| Ali, I; Choi, G; Go, A; Lee, J; Lee, K | 1 |
| Alam, O; Amir, M; Tariq, S | 1 |
| Ahmed, HEA; Alswah, M; Bayoumi, AH; Elgamal, K; Elmorsy, A; Ihmaid, S | 1 |
| Ankrom, W; Fan, L; Iwamoto, M; Khalilieh, S; Mitra, P; Sanchez, RI; Sterling, LM; Stoch, SA; Triantafyllou, I; Wolford, D; Yee, KL | 1 |
| Avdonin, PP; Avdonin, PV; Goncharov, NV; Mironova, GY; Nadeev, AD; Zharkikh, IL | 1 |
| Adhikari, P; Ayo, TE; Sugita, S; Xu, H | 1 |
| Barakat, A; Boraei, ATA; Sarhan, AAM; Yousuf, S | 1 |
| Afifi, TH; Ahmed, HEA; Alswah, M; Bayoumi, AH; El-Gamal, KM; El-Morsy, A; Ghiaty, A; Mansour, BA; Mohammed, AS; Omar, AM; Sherbiny, FF | 1 |
| Abulkhair, HS; Alswah, M; Bayoumi, AH; El-Morsy, AM; Ezzat, HG; Ghiaty, A; Sherbiny, FF | 1 |
| Aggarwal, H; Ewa, AK; Ghosh, B; Głogowska, A; Kumar, BK; Murugesan, S; Nandikolla, A; Pulya, S; Sekhar, KVGC; Srinivasarao, S; Suresh, A | 1 |
| Chen, K; Hou, H; Liu, X; Wu, X; Yang, R; Zhang, S; Zheng, M | 1 |
| Kaneko, D; Koketsu, M; Ninomiya, M; Nishina, A; Ono, Y; Sonawane, AD; Tanaka, K; Yoshikawa, R | 1 |
| El-Adl, K; El-Helby, AA; Elwan, A; Sakr, H | 1 |
| Abidi, SH; Ali, S; Allemailem, KS; Almansour, NM; Amerzhanov, D; Ibrahim, MAA; la Fleur, P; Lukac, M; Rafaqat, W | 1 |
| Al-Mehizia, AA; Alanazi, MM; Alkahtani, HM; Alsaif, NA; Alsubaie, SM; Dahab, MA; Eissa, IH; Mahdy, HA; Obaidullah, AJ | 1 |
| Alanazi, MM; Alanazi, WA; Alasmari, A; Albassam, H; Alsaif, NA; Dahab, MA; Mahdy, HA; Obaidullah, AJ; Taghour, MS | 1 |
| Al-Hossaini, AM; Al-Mehizi, AA; Alanazi, MM; Alkahtani, HM; Alsaif, NA; Elwan, A; Mahdy, HA; Obaidullah, AJ; Taghour, MS | 1 |
| Hoffman, GR; Schoffstall, AM | 1 |
5 review(s) available for triazoles and quinoxalines
| Article | Year |
|---|---|
[New fluorogenic dienophile: synthesis, reaction with vitamin D, vitamin A and microcystins, and application to fluorometric assays].
Topics: Fluorescent Dyes; Fluorometry; Humans; Microcystins; Peptides, Cyclic; Quinoxalines; Triazoles; Vitamin A; Vitamin D | 1995 |
What's new in clinical pharmacology and therapeutics.
Topics: Abatacept; Acetanilides; Amides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiparkinson Agents; Antirheumatic Agents; Antiviral Agents; Apomorphine; Benzazepines; Cardiovascular Agents; Fumarates; Hepatitis B; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; Humans; Hypoglycemic Agents; Immunoconjugates; Multiple Sclerosis; Natalizumab; Nucleosides; Papillomavirus Vaccines; Pharmacology, Clinical; Piperazines; Pyrazines; Pyrimidinones; Quinoxalines; Ranolazine; Sitagliptin Phosphate; Smoking Cessation; Telbivudine; Thymidine; Triazoles; Varenicline; Viral Vaccines | 2008 |
Vitamin D metabolite profiling using liquid chromatography-tandem mass spectrometry (LC-MS/MS).
Topics: Animals; Binding, Competitive; Calcifediol; Chromatography, Liquid; Female; Genotype; Guinea Pigs; Humans; Male; Mice; Mice, Knockout; Protein Binding; Quinoxalines; Radioimmunoassay; Reproducibility of Results; Tandem Mass Spectrometry; Triazoles; Vitamin D | 2016 |
NewDrugs 2017, part 2.
Topics: Amides; Antibodies, Monoclonal, Humanized; Benzofurans; Carbamates; Cyclopropanes; Drug Approval; Drug Therapy; gamma-Cyclodextrins; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Peptides; Phenylalanine; Quinoxalines; Sofosbuvir; Sugammadex; Sulfonamides; Sulfones; Thioglycolates; Triazoles; United States; United States Food and Drug Administration | 2017 |
Syntheses and Applications of 1,2,3-Triazole-Fused Pyrazines and Pyridazines.
Topics: Pyrazines; Pyridazines; Quinoxalines; Triazoles | 2022 |
2 trial(s) available for triazoles and quinoxalines
| Article | Year |
|---|---|
Brimonidine versus dapiprazole: Influence on pupil size at various illumination levels.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Brimonidine Tartrate; Dark Adaptation; Diagnostic Techniques, Ophthalmological; Humans; Light; Ophthalmic Solutions; Piperazines; Prospective Studies; Pupil; Quinoxalines; Triazoles | 2005 |
Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Letrozole; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Staging; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retreatment; Sulfonamides; Treatment Outcome; Triazoles | 2015 |
84 other study(ies) available for triazoles and quinoxalines
| Article | Year |
|---|---|
Fluorometric assay of 25-hydroxyvitamin D3 and 24R,25-dihydroxyvitamin D3 in plasma.
Topics: 24,25-Dihydroxyvitamin D 3; Calcifediol; Chromatography, High Pressure Liquid; Fluorescent Dyes; Humans; Quinoxalines; Spectrometry, Fluorescence; Triazoles | 1992 |
A rapid in vivo bioassay for the carcinogenicity of pesticides.
Topics: Animals; Benomyl; Captan; Carcinogenicity Tests; Imidazoles; Male; Pesticides; Phosmet; Phthalimides; Quinoxalines; Rats; Rats, Inbred F344; Succinates; Triazoles | 1991 |
Synthesis of a reagent for fluorescence-labeling of vitamin D and its use in assaying vitamin D metabolites.
Topics: 24,25-Dihydroxyvitamin D 3; Calcifediol; Chromatography, High Pressure Liquid; Fluorescent Dyes; Fluorometry; Quinoxalines; Triazoles; Vitamin D | 1991 |
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.
Topics: Adenosine; Adenosine-5'-(N-ethylcarboxamide); Animals; Antidepressive Agents; Behavior, Animal; Caffeine; Cats; Cell Membrane; Cerebral Cortex; Chemical Phenomena; Chemistry; Corpus Striatum; Male; Molecular Structure; Motor Activity; Purinergic Antagonists; Quinoxalines; Rats; Receptors, Purinergic; Sleep; Structure-Activity Relationship; Triazoles | 1990 |
1,2,4-Triazolo[4,3-a]quinoxaline-1,4-diones as antiallergic agents.
Topics: Animals; Histamine H1 Antagonists; Histamine Release; Hypersensitivity; Male; Passive Cutaneous Anaphylaxis; Quinoxalines; Rats; Rats, Inbred Strains; Structure-Activity Relationship; Triazoles | 1985 |
[1,2,4]Triazolo[4,3-a]quinoxalin-4-amines: a new class of A1 receptor selective adenosine antagonists.
Topics: Animals; Brain; Chemical Phenomena; Chemistry; In Vitro Techniques; Quinoxalines; Rats; Receptors, Purinergic; Structure-Activity Relationship; Triazoles | 1988 |
In vivo anti-allergic and bronchopulmonary pharmacology of REV 3164 in rats and guinea-pigs.
Topics: Animals; Antibody Formation; Asthma; Bronchi; Guinea Pigs; Histamine Antagonists; Immunoglobulin E; Immunoglobulin G; Male; p-Methoxy-N-methylphenethylamine; Parasympatholytics; Passive Cutaneous Anaphylaxis; Quinoxalines; Rats; Rats, Inbred Strains; Respiratory System; Serotonin Antagonists; Species Specificity; SRS-A; Time Factors; Triazoles | 1984 |
Structure-activity relationships of 1,2,4-triazolo[1,5-a] quinoxalines and their 1-deaza analogues imidazo[1,2-a]quinoxalines at the benzodiazepine receptor.
Topics: Animals; Binding Sites; Binding, Competitive; Brain; Cattle; Flunitrazepam; Imidazoles; In Vitro Techniques; Quinoxalines; Receptors, GABA-A; Structure-Activity Relationship; Triazoles | 1994 |
Platelet-activating factor inhibits excitatory transmission in rat neostriatum.
Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Action Potentials; Animals; Azepines; Glutamates; Glutamic Acid; Neostriatum; Neural Inhibition; Platelet Activating Factor; Platelet Membrane Glycoproteins; Quinoxalines; Rats; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Triazoles | 1993 |
Tricyclic heteroaromatic systems 1,2,4-triazolo[1,5-a]quinoxalines: synthesis and benzodiazepine receptor activity.
Topics: Animals; Binding, Competitive; Cattle; Cerebral Cortex; Chlordiazepoxide; Flunitrazepam; In Vitro Techniques; Quinoxalines; Receptors, GABA-A; Triazoles | 1993 |
Fluorimetric assay of 1 alpha,25-dihydroxyvitamin D3 in human plasma.
Topics: Adult; Calcitriol; Chromatography, High Pressure Liquid; Fluorescent Dyes; Fluorometry; Humans; Middle Aged; Quinoxalines; Reproducibility of Results; Sensitivity and Specificity; Triazoles | 1997 |
Synthesis and antifungal activity of some imidazo, pyrazino and v-triazoloquinoxalines.
Topics: Antifungal Agents; Aspergillus flavus; Aspergillus niger; Candida albicans; Chemical Phenomena; Chemistry, Physical; Cyclization; Fungi; Imidazoles; Microbial Sensitivity Tests; Pyrazines; Quinoxalines; Triazoles | 1997 |
Synthesis and antimicrobial testing of thiazolinyl-, thiazolidinonyl-quinoxalines and 1,2,4-triazolo[4,3-a]quinoxalines.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Candida albicans; Escherichia coli; Microbial Sensitivity Tests; Quinoxalines; Staphylococcus aureus; Thiazoles; Triazoles | 1997 |
Tricyclic heteroaromatic systems. 1,2,4-triazolo[4,3-a]quinoxalines and 1,2,4-Triazino[4,3-a]quinoxalines: synthesis and central benzodiazepine receptor activity.
Topics: Animals; Cerebral Cortex; Male; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, GABA-A; Structure-Activity Relationship; Triazoles | 1997 |
High-performance liquid chromatographic separation of microcystins derivatized with a highly fluorescent dienophile.
Topics: Bacterial Toxins; Chromatography, High Pressure Liquid; Cyanobacteria; Fluorescent Dyes; Luminescent Measurements; Marine Toxins; Microcystins; Peptides, Cyclic; Quinoxalines; Spectrometry, Fluorescence; Triazoles | 1997 |
1-substituted 4-[chloropyrazolyl][1,2,4]triazolo[4,3-a]quinoxalines: synthesis and structure-activity relationships of a new class of benzodiazepine and adenosine receptor ligands.
Topics: Animals; GABA-A Receptor Antagonists; Ligands; Purinergic P1 Receptor Antagonists; Pyrazoles; Quinoxalines; Rats; Structure-Activity Relationship; Triazoles | 1998 |
4-Amino-6-benzylamino-1,2-dihydro-2-phenyl-1,2,4-triazolo [4,3-alpha]-quinoxalin-1-one: a new A2A adenosine receptor antagonist with high selectivity versus A1 receptors.
Topics: Animals; Binding Sites; Cattle; Purinergic P1 Receptor Antagonists; Pyrimidines; Quinoxalines; Receptor, Adenosine A2A; Receptors, Purinergic P1; Structure-Activity Relationship; Triazoles | 1999 |
7-Chloro-4,5-dihydro-8-(1,2,4-triazol-4-yl)-4-oxo-1,2,4-triazolo[1, 5-a]quinoxaline-2- carboxylates as novel highly selective AMPA receptor antagonists.
Topics: Animals; Cerebral Cortex; Electrophysiology; Excitatory Amino Acid Antagonists; In Vitro Techniques; Mice; Quinoxalines; Receptors, AMPA; Structure-Activity Relationship; Triazoles | 2000 |
Nitric oxide inhibition of cAMP synthesis in parotid acini: regulation of type 5/6 adenylyl cyclase.
Topics: Adenylyl Cyclases; Animals; Calcium; Cells, Cultured; Colforsin; Cyclic AMP; Cyclic GMP; Dose-Response Relationship, Drug; Enzyme Inhibitors; Isoenzymes; Isoproterenol; Mice; Nitric Oxide; Nitric Oxide Donors; Oxadiazoles; Parotid Gland; Phosphoric Diester Hydrolases; Quinoxalines; Thapsigargin; Triazoles | 2001 |
Synthesis and antibacterial activity of fused 1, 2, 4-triazolo[4, 3-a]quinoxaline and oxopyrimido[2', 1':5, 1]-1, 2, 4-triazolo[4, 3-a]quinoxaline derivatives.
Topics: Anti-Bacterial Agents; Bacteria; Chemical Phenomena; Chemistry, Physical; Ciprofloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Indicators and Reagents; Microbial Sensitivity Tests; Pyrimidines; Quinoxalines; Triazoles | 2002 |
Synthesis of certain substituted quinoxalines as antimicrobial agents (Part II).
Topics: Anti-Bacterial Agents; Bacillus subtilis; Escherichia coli; Microbial Sensitivity Tests; Molecular Structure; Quinoxalines; Staphylococcus aureus; Triazoles | 2003 |
Synthesis and biological evaluation of analogues of 7-chloro-4,5-dihydro-4- oxo-8-(1,2,4-triazol-4-yl)-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylic acid (TQX-173) as novel selective AMPA receptor antagonists.
Topics: Animals; Brain; Electrophysiology; In Vitro Techniques; Quinoxalines; Radioligand Assay; Rats; Receptors, AMPA; Receptors, Glycine; Receptors, Kainic Acid; Receptors, N-Methyl-D-Aspartate; Structure-Activity Relationship; Synaptic Membranes; Synaptosomes; Triazines; Triazoles | 2004 |
Synthesis and structure-activity relationships of 4-cycloalkylamino-1, 2, 4-triazolo[4, 3-a]quinoxalin-1- one derivatives as A1 and A3 adenosine receptor antagonists.
Topics: Adenosine; Alkanes; Animals; Binding Sites; Binding, Competitive; Cattle; Cerebral Cortex; CHO Cells; Cricetinae; Humans; Iodine Isotopes; Membranes; Neostriatum; Phenethylamines; Purinergic Antagonists; Quantitative Structure-Activity Relationship; Quinoxalines; Receptors, Purinergic; Triazoles; Tritium | 2004 |
1,2,4-Triazolo[1,5-a]quinoxaline derivatives: synthesis and biological evaluation as adenosine receptor antagonists.
Topics: Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Adenosine A3 Receptor Antagonists; Animals; Binding, Competitive; Cattle; Cerebral Cortex; CHO Cells; Cricetinae; Humans; In Vitro Techniques; Indicators and Reagents; Kinetics; Magnetic Resonance Spectroscopy; Neostriatum; Purinergic P1 Receptor Antagonists; Quinoxalines; Spectrophotometry, Infrared; Structure-Activity Relationship; Triazoles | 2004 |
Development of behavioral sensitization to the cocaine-like fungicide triadimefon is prevented by AMPA, NMDa, DA D1 but not DA D2 receptor antagonists.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Behavior, Animal; Benzazepines; Brain Chemistry; Corpus Striatum; Drug Administration Schedule; Fungicides, Industrial; Male; Mice; Mice, Inbred C57BL; Motor Activity; N-Methylaspartate; Neuronal Plasticity; Piperazines; Quinoxalines; Receptors, AMPA; Receptors, Dopamine D1; Receptors, N-Methyl-D-Aspartate; Remoxipride; Substance Withdrawal Syndrome; Time Factors; Triazoles | 2004 |
1,2,4-triazolo[4,3-a]quinoxalin-1-one moiety as an attractive scaffold to develop new potent and selective human A3 adenosine receptor antagonists: synthesis, pharmacological, and ligand-receptor modeling studies.
Topics: Adenosine A3 Receptor Antagonists; Animals; Cattle; CHO Cells; Cricetinae; Humans; Ligands; Models, Molecular; Quinoxalines; Radioligand Assay; Receptor, Adenosine A3; Structure-Activity Relationship; Triazoles | 2004 |
Production and release of yessotoxins by the dinoflagellates Protoceratium reticulatum and Lingulodinium polyedrum in culture.
Topics: Animals; Chromatography, High Pressure Liquid; Culture Media; Dinoflagellida; Ethers, Cyclic; Mass Spectrometry; Microscopy, Fluorescence; Mollusk Venoms; Oxocins; Quinoxalines; Triazoles | 2004 |
Derivatives of 4,6-diamino-1,2-dihydro-2-phenyl-1,2,4-triazolo[4,3-a]quinoxalin-2H-1-one: potential antagonist ligands for imaging the A2A adenosine receptor by positron emission tomography (PET).
Topics: Adenosine A2 Receptor Antagonists; Animals; Autoradiography; Binding, Competitive; Brain; Ligands; Magnetic Resonance Spectroscopy; Molecular Structure; Positron-Emission Tomography; Quinoxalines; Radioligand Assay; Rats; Spectrometry, Mass, Electrospray Ionization; Triazoles; Tritium | 2005 |
Dual impact of a nitric oxide donor, GEA 3175, in human pulmonary smooth muscle.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Albuterol; Bronchi; Bronchodilator Agents; Dose-Response Relationship, Drug; Female; Humans; In Vitro Techniques; Male; Muscle Contraction; Muscle, Smooth; Nitric Oxide; Nitric Oxide Donors; Oxadiazoles; Peptides; Pulmonary Artery; Quinoxalines; Triazoles; Vasoconstrictor Agents; Vasodilation | 2005 |
Cross-talk between adenosine and the oxatriazole derivative GEA 3175 in platelets.
Topics: Adenosine; Blood Platelets; Calcium; Cyclic AMP; Cyclic GMP; Cytosol; Drug Interactions; Enzyme Inhibitors; Guanylate Cyclase; Humans; Milrinone; Oxadiazoles; Phosphodiesterase Inhibitors; Platelet Aggregation; Platelet Aggregation Inhibitors; Quinoxalines; Thrombin; Time Factors; Triazoles | 2005 |
Involvement of guanylyl cyclase, protein kinase A and Na+ K+ ATPase in relaxations of bovine isolated bronchioles induced by GEA 3175, an NO donor.
Topics: Animals; Bronchi; Calcium; Cattle; Colforsin; Cyclic AMP; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Guanylate Cyclase; In Vitro Techniques; Molsidomine; Muscle Relaxation; Nitric Oxide; Nitric Oxide Donors; Ouabain; Oxadiazoles; Peptides; Potassium; Quinoxalines; S-Nitrosoglutathione; Serotonin; Sodium-Potassium-Exchanging ATPase; Thionucleotides; Triazoles | 2006 |
Estrogen synthesis in the central nucleus of the amygdala following middle cerebral artery occlusion: role in modulating neurotransmission.
Topics: Amygdala; Animals; Aromatase Inhibitors; Autonomic Nervous System; Blood Pressure; Brain Chemistry; Estradiol; Estrogen Antagonists; Estrogens; Excitatory Amino Acid Antagonists; Fulvestrant; Heart Rate; Infarction, Middle Cerebral Artery; Injections, Intraventricular; Letrozole; Male; Microdialysis; Nitriles; Piperazines; Quinoxalines; Rats; Rats, Sprague-Dawley; Synaptic Transmission; Testosterone; Triazoles | 2005 |
Dual actions of dephostatin on the nitric oxide/cGMP-signalling pathway in porcine iliac arteries.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Acetylcholine; Animals; Blotting, Western; Cyclic GMP; Enzyme Inhibitors; Guanylate Cyclase; Hydroquinones; Iliac Artery; In Vitro Techniques; Nitric Oxide; Nitric Oxide Donors; Oxadiazoles; Penicillamine; Phenylephrine; Phosphoproteins; Phosphorylation; Protein Tyrosine Phosphatases; Quinoxalines; Serine; Signal Transduction; Swine; Triazoles; Tyrosine; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2005 |
1,2,4-Triazolo[1,5-a]quinoxaline as a versatile tool for the design of selective human A3 adenosine receptor antagonists: synthesis, biological evaluation, and molecular modeling studies of 2-(hetero)aryl- and 2-carboxy-substituted derivatives.
Topics: Adenosine A3 Receptor Antagonists; Amino Acid Motifs; Animals; Binding Sites; Cattle; Cerebral Cortex; Corpus Striatum; Drug Design; Humans; In Vitro Techniques; Models, Molecular; Quinoxalines; Radioligand Assay; Receptor, Adenosine A3; Structure-Activity Relationship; Triazoles | 2005 |
4-amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as new potent and selective human A3 adenosine receptor antagonists. synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
Topics: Adenosine A3 Receptor Antagonists; Animals; Binding, Competitive; Cattle; Cerebral Cortex; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; Humans; In Vitro Techniques; Ligands; Membranes; Models, Molecular; Quinoxalines; Radioligand Assay; Structure-Activity Relationship; Triazoles | 2006 |
4-Substituted anilino imidazo[1,2-a] and triazolo[4,3-a]quinoxalines. Synthesis and evaluation of in vitro biological activity.
Topics: Cell Line; Cell Proliferation; Humans; Imidazoles; Molecular Structure; Quinoxalines; Structure-Activity Relationship; Triazoles | 2006 |
Synthesis of some new quinoxalines and 1,2,4-triazolo[4,3-a]-quinoxalines for evaluation of in vitro antitumor and antimicrobial activities.
Topics: Anti-Infective Agents; Antineoplastic Agents; Candida albicans; Cefotaxime; Cell Line, Tumor; Cell Survival; Dimethylformamide; Dose-Response Relationship, Drug; Escherichia coli; Humans; Microbial Sensitivity Tests; Molecular Structure; Nystatin; Quinoxalines; Staphylococcus aureus; Structure-Activity Relationship; Triazoles | 2006 |
The suppressant effect of GEA3162 on spontaneous serotonin release from human colonic mucosa in vitro.
Topics: Calcium Channel Blockers; Chromatography, High Pressure Liquid; Colon; Electrochemistry; Enzyme Inhibitors; Gastrointestinal Hormones; Guanylate Cyclase; Hydroxyindoleacetic Acid; Intestinal Mucosa; Natriuretic Peptides; NG-Nitroarginine Methyl Ester; Nicardipine; Nitric Oxide Donors; Nitric Oxide Synthase; Oxadiazoles; Peroxynitrous Acid; Quinoxalines; Serotonin; Triazoles | 2006 |
Drug approvals.
Topics: Acetanilides; Alprostadil; Angina Pectoris; Benzazepines; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Drug Approval; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Fatty Acids; Herpes Zoster Vaccine; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; Humans; Ibandronic Acid; Insulin; Lubiprostone; Naltrexone; Narcotic Antagonists; Nurse's Role; Papillomavirus Vaccines; Patient Education as Topic; Piperazines; Quinoxalines; Ranolazine; Triazoles; United States; United States Food and Drug Administration; Varenicline | 2007 |
Quantitative structure-activity relationship study of human A3 adenosine receptor antagonists: derivatives of 2-aryl-1,2,4-triazolo [4,3-alpha]quinoxaline.
Topics: Adenosine A3 Receptor Antagonists; Quantitative Structure-Activity Relationship; Quinoxalines; Triazoles | 2007 |
A class of small molecules that inhibit TNFalpha-induced survival and death pathways via prevention of interactions between TNFalphaRI, TRADD, and RIP1.
Topics: Apoptosis; Cell Membrane; Enzyme Inhibitors; Epithelial Cells; Gene Expression Regulation; Intercellular Adhesion Molecule-1; Lung; Quinoxalines; Receptor-Interacting Protein Serine-Threonine Kinases; Receptors, Tumor Necrosis Factor, Type I; Signal Transduction; Small Molecule Libraries; TNF Receptor-Associated Death Domain Protein; Triazoles; Tumor Necrosis Factor-alpha | 2007 |
Scouting human A3 adenosine receptor antagonist binding mode using a molecular simplification approach: from triazoloquinoxaline to a pyrimidine skeleton as a key study.
Topics: Adenosine A3 Receptor Antagonists; Animals; Binding Sites; Binding, Competitive; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; Humans; Models, Molecular; Pyrimidines; Quinoxalines; Radioligand Assay; Receptor, Adenosine A3; Triazoles | 2007 |
Synthesis, ligand-receptor modeling studies and pharmacological evaluation of novel 4-modified-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as potent and selective human A3 adenosine receptor antagonists.
Topics: Adenosine A3 Receptor Antagonists; Animals; Binding, Competitive; Brain Ischemia; Cattle; Cell Membrane; Cerebral Cortex; Disease Models, Animal; Humans; Hydrogen Bonding; Ligands; Models, Molecular; Protein Binding; Quinoxalines; Rats; Receptor, Adenosine A3; Rhodopsin; Structural Homology, Protein; Structure-Activity Relationship; Triazoles; Xanthines | 2008 |
Aceclidine, brimonidine tartrate, and dapiprazole: comparison of miotic effect and tolerability under different lighting conditions.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adult; Brimonidine Tartrate; Female; Humans; Light; Male; Middle Aged; Parasympatholytics; Piperazines; Prospective Studies; Pupil; Quinoxalines; Quinuclidines; Surveys and Questionnaires; Triazoles | 2009 |
3D-QSAR studies for the binding affinity toward (R, S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)-propionic acid receptor.
Topics: Anticonvulsants; Binding Sites; Computer Simulation; Computer-Aided Design; Drug Design; Excitatory Amino Acid Antagonists; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Imaging, Three-Dimensional; Least-Squares Analysis; Models, Molecular; Molecular Structure; Protein Conformation; Quantitative Structure-Activity Relationship; Quinoxalines; Receptors, AMPA; Static Electricity; Triazoles | 2008 |
Findings on alcohol dependence point to promising avenues for targeted therapies.
Topics: Alcoholism; Animals; Benzazepines; Humans; Naltrexone; Narcotic Antagonists; Neurokinin-1 Receptor Antagonists; Nicotinic Agonists; Pharmacogenetics; Pyridines; Quinoxalines; Receptors, Corticotropin-Releasing Hormone; Receptors, Opioid, mu; Stress, Psychological; Triazoles; Varenicline | 2009 |
Chloracne in seven organic chemists exposed to novel polycyclic halogenated chemical compounds (triazoloquinoxalines).
Topics: Accidents, Occupational; Adult; Chloracne; Humans; Male; Occupational Diseases; Occupational Exposure; Quinoxalines; Triazoles; Young Adult | 2009 |
Long-term potentiation in the rat medial vestibular nuclei depends on locally synthesized 17beta-estradiol.
Topics: Animals; Animals, Newborn; Aromatase Inhibitors; Bicuculline; Biophysics; Drug Interactions; Electric Stimulation; Estradiol; Estrogen Antagonists; Excitatory Amino Acid Antagonists; Fulvestrant; GABA Antagonists; In Vitro Techniques; Letrozole; Long-Term Potentiation; Male; Nitriles; Quinoxalines; Rats; Rats, Wistar; Triazoles; Valine; Vestibular Nuclei | 2009 |
Effectiveness of daily use of brimonidine as antimydriatic agent.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Brimonidine Tartrate; Humans; Light; Parasympatholytics; Piperazines; Pupil; Quinoxalines; Quinuclidines; Surveys and Questionnaires; Treatment Outcome; Triazoles | 2009 |
Efficient Pd-catalyzed coupling of tautomerizable heterocycles with terminal alkynes via C-OH bond activation using PyBrOP.
Topics: Alkynes; Catalysis; Heterocyclic Compounds; Molecular Structure; Organometallic Compounds; Organophosphorus Compounds; Palladium; Quinoxalines; Stereoisomerism; Triazoles | 2010 |
Ligand-based virtual screening and ADME-tox guided approach to identify triazolo-quinoxalines as folate cycle inhibitors.
Topics: Cell Line, Tumor; Enzyme Inhibitors; Folic Acid; Folic Acid Antagonists; Humans; Ligands; Quinoxalines; Tetrahydrofolate Dehydrogenase; Thymidylate Synthase; Triazoles | 2010 |
Synthesis and characterization of [1,2,5]chalcogenazolo[3,4-f]benzo[1,2,3]triazole and [1,2,3]triazolo[3,4-g]quinoxaline derivatives.
Topics: Molecular Structure; Quinoxalines; Stereoisomerism; Triazoles | 2011 |
Copper(II) chloride mediated synthesis and DNA photocleavage activity of 1-aryl/heteroaryl-4-substituted-1,2,4-triazolo[4,3-a]quinoxalines.
Topics: Copper; Cyclization; DNA Cleavage; DNA, Superhelical; Oxidation-Reduction; Photolysis; Plasmids; Quinoxalines; Triazoles; Ultraviolet Rays | 2011 |
Highly potent and selective fluorescent antagonists of the human adenosine A₃ receptor based on the 1,2,4-triazolo[4,3-a]quinoxalin-1-one scaffold.
Topics: Adenosine A3 Receptor Antagonists; Animals; Boron Compounds; Cell Membrane; CHO Cells; Cricetinae; Cricetulus; Fluorescent Dyes; HEK293 Cells; Humans; Ligands; Models, Molecular; Quinoxalines; Stereoisomerism; Structure-Activity Relationship; Triazoles | 2012 |
Synthesis of [1,2,3]triazolo[1,5-a]quinoxalin-4(5H)-ones through copper-catalyzed tandem reactions of N-(2-haloaryl)propiolamides with sodium azide.
Topics: Amides; Catalysis; Copper; Cyclization; Molecular Structure; Quinoxalines; Sodium Azide; Triazoles | 2012 |
[Peripheral mechanisms of action of oxatriazolium-5-olate derivative 3-(3-[1,2,4]-triazolo)oxatriazolium-5-olate in spontaneously hypertensive rats].
Topics: Animals; Arteries; Guanylate Cyclase; Heme; Male; Nitric Oxide; Nitroprusside; Oxadiazoles; Phenylephrine; Quinoxalines; Rats; Rats, Inbred SHR; Rats, Wistar; Tail; Tissue Culture Techniques; Triazoles; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2012 |
TNF-alpha receptor antagonist, R-7050, improves neurological outcomes following intracerebral hemorrhage in mice.
Topics: Animals; Blood-Brain Barrier; Brain; Brain Edema; Cerebral Hemorrhage; Hematoma; Male; Mice; Neuroprotective Agents; Quinoxalines; Receptors, Tumor Necrosis Factor, Type I; Triazoles; Tumor Necrosis Factor-alpha | 2013 |
Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia.
Topics: Animals; Azepines; Electroencephalography; Electromyography; Indoles; Male; Mice; Mice, Inbred C57BL; Motor Activity; Orexin Receptor Antagonists; Pyrimidines; Quinoxalines; Sleep; Sleep Initiation and Maintenance Disorders; Sleep Stages; Spiro Compounds; Stereoisomerism; Structure-Activity Relationship; Triazoles | 2013 |
Crystal structure and pharmacological characterization of a novel N-methyl-D-aspartate (NMDA) receptor antagonist at the GluN1 glycine binding site.
Topics: Animals; Binding Sites; Carrier Proteins; Crystallography, X-Ray; Nerve Tissue Proteins; Protein Binding; Protein Structure, Tertiary; Quinoxalines; Rats; Receptors, N-Methyl-D-Aspartate; Triazoles; Xenopus laevis | 2013 |
Clinical utility of simultaneous quantitation of 25-hydroxyvitamin D and 24,25-dihydroxyvitamin D by LC-MS/MS involving derivatization with DMEQ-TAD.
Topics: 24,25-Dihydroxyvitamin D 3; Animals; Blood Chemical Analysis; Chromatography, Liquid; Dietary Supplements; Female; Humans; Hypercalcemia; Mice; Mice, Knockout; Predictive Value of Tests; Quinoxalines; Tandem Mass Spectrometry; Triazoles; Vitamin D; Vitamin D Deficiency | 2014 |
72nd annual meeting of the American Academy of Dermatology.
Topics: Antifungal Agents; Attention Deficit Disorder with Hyperactivity; Boron Compounds; Botulinum Toxins, Type A; Bridged Bicyclo Compounds, Heterocyclic; Brimonidine Tartrate; Depression; Dermatitis, Atopic; Food Hypersensitivity; Humans; Immunologic Factors; Ivermectin; Phosphodiesterase Inhibitors; Phototherapy; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinoxalines; Skin Diseases; Societies, Medical; Thalidomide; Triazoles; United States | 2014 |
Simple synthesis of new carbon-11-labeled 1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives for PET imaging of A₃ adenosine receptor.
Topics: Carbon Radioisotopes; Isotope Labeling; Magnetic Resonance Spectroscopy; Positron-Emission Tomography; Quinoxalines; Radiopharmaceuticals; Receptor, Adenosine A3; Spectrometry, Mass, Electrospray Ionization; Triazoles | 2014 |
CNS drug development: lessons from the development of ondansetron, aprepitant, ramelteon, varenicline, lorcaserin, and suvorexant. Part I.
Topics: Aprepitant; Azepines; Benzazepines; Central Nervous System Agents; Drug Discovery; History, 20th Century; History, 21st Century; Humans; Indenes; Morpholines; Neurotransmitter Agents; Ondansetron; Quinoxalines; Triazoles; Varenicline | 2014 |
Characterisation of Lu AF33241: A novel, brain-penetrant, dual inhibitor of phosphodiesterase (PDE) 2A and PDE10A.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Blood-Brain Barrier; Capillary Permeability; Catalepsy; Cognition; Cyclic Nucleotide Phosphodiesterases, Type 2; Exploratory Behavior; Humans; Male; Motor Activity; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Quinoxalines; Rats, Sprague-Dawley; Rats, Wistar; Recognition, Psychology; Triazoles | 2015 |
Double Sonogashira reactions on dihalogenated aminopyridines for the assembly of an array of 7-azaindoles bearing triazole and quinoxaline substituents at C-5: Inhibitory bioactivity against Giardia duodenalis trophozoites.
Topics: Aminopyridines; Antiparasitic Agents; Aza Compounds; Giardia lamblia; Halogenation; Indoles; Quinoxalines; Structure-Activity Relationship; Triazoles; Trophozoites | 2015 |
Effect of carbon chain length in acyl coenzyme A on the efficiency of enzymatic transformation of okadaic acid to 7-O-acyl okadaic acid.
Topics: Acyl Coenzyme A; Acylation; Animals; Click Chemistry; Fatty Acids; Fluorescent Dyes; Microsomes; Okadaic Acid; Pectinidae; Pyrans; Quinoxalines; Structure-Activity Relationship; Triazoles | 2016 |
The JAK2 inhibitors CEP-33779 and NVP-BSK805 have high P-gp inhibitory activity and sensitize drug-resistant cancer cells to vincristine.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Janus Kinase 2; Protein Kinase Inhibitors; Pyridines; Quinoxalines; Structure-Activity Relationship; Triazoles; Tumor Cells, Cultured; Vincristine | 2017 |
Discovery of novel [1,2,4]triazolo[4,3-a]quinoxaline aminophenyl derivatives as BET inhibitors for cancer treatment.
Topics: Animals; Antineoplastic Agents; Binding Sites; Cell Cycle Checkpoints; Cell Line, Tumor; Drug Evaluation, Preclinical; Half-Life; Humans; Inhibitory Concentration 50; Molecular Docking Simulation; Neoplasms; Nuclear Proteins; Protein Structure, Tertiary; Proto-Oncogene Proteins c-myc; Quinoxalines; Rats; Structure-Activity Relationship; Triazoles | 2017 |
Synthesis, anti-inflammatory, p38α MAP kinase inhibitory activities and molecular docking studies of quinoxaline derivatives containing triazole moiety.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Enzyme Assays; Female; Lipid Peroxidation; Male; Mitogen-Activated Protein Kinase 14; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Quinoxalines; Rats, Wistar; Stomach Ulcer; Triazoles | 2018 |
Design, Synthesis and Cytotoxic Evaluation of Novel Chalcone Derivatives Bearing Triazolo[4,3-a]-quinoxaline Moieties as Potent Anticancer Agents with Dual EGFR Kinase and Tubulin Polymerization Inhibitory Effects.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chalcone; Colchicine; Drug Design; ErbB Receptors; Humans; Magnetic Resonance Spectroscopy; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Quinoxalines; Spectrometry, Mass, Electrospray Ionization; Structure-Activity Relationship; Triazoles; Tubulin; Tubulin Modulators | 2017 |
Investigation of Pharmacokinetic Interactions between Doravirine and Elbasvir-Grazoprevir and Ledipasvir-Sofosbuvir.
Topics: Adult; Amides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Interactions; Female; Fluorenes; Humans; Imidazoles; Least-Squares Analysis; Male; Middle Aged; Pyridones; Quinoxalines; Sulfonamides; Triazoles | 2019 |
Enhancement by Hydrogen Peroxide of Calcium Signals in Endothelial Cells Induced by 5-HT1B and 5-HT2B Receptor Agonists.
Topics: Acetylcysteine; Benzoxazoles; Calcium; Calcium Signaling; Fluorescence; Human Umbilical Vein Endothelial Cells; Humans; Hydrogen Peroxide; Indoles; Quinoxalines; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT2B; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Agonists; Thiophenes; Triazoles; Vanadates | 2019 |
TNF Production in Activated RBL-2H3 Cells Requires Munc13-4.
Topics: Animals; Cell Degranulation; Gene Knockout Techniques; Mast Cells; Membrane Proteins; Mice; Quinoxalines; Signal Transduction; Triazoles; Tumor Necrosis Factor-alpha | 2020 |
Synthesis of a New Series of Nitrogen/Sulfur Heterocycles by Linking Four Rings: Indole; 1,2,4-Triazole; Pyridazine; and Quinoxaline.
Topics: Carbon-13 Magnetic Resonance Spectroscopy; Heterocyclic Compounds; Hydrogen Bonding; Indoles; Molecular Conformation; Nitrogen; Proton Magnetic Resonance Spectroscopy; Pyridazines; Quinoxalines; Sulfur; Triazoles; X-Ray Diffraction | 2020 |
Antimicrobial screening and pharmacokinetic profiling of novel phenyl-[1,2,4]triazolo[4,3-a]quinoxaline analogues targeting DHFR and E. coli DNA gyrase B.
Topics: Anti-Bacterial Agents; DNA Gyrase; Escherichia coli; Escherichia coli Infections; Folic Acid Antagonists; Humans; Models, Molecular; Quinoxalines; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Topoisomerase II Inhibitors; Triazoles | 2020 |
Design, synthesis, and molecular docking studies of new [1,2,4]triazolo[4,3-a]quinoxaline derivatives as potential A2B receptor antagonists.
Topics: Adenosine A2 Receptor Antagonists; Cell Line, Tumor; Drug Design; Humans; Inhibitory Concentration 50; Molecular Docking Simulation; Quinoxalines; Structure-Activity Relationship; Triazoles | 2021 |
Discovery of 1,2,3-triazole based quinoxaline-1,4-di-N-oxide derivatives as potential anti-tubercular agents.
Topics: Antitubercular Agents; Binding Sites; Catalytic Domain; Cell Survival; Crystallography, X-Ray; DNA Gyrase; Drug Design; Drug Evaluation, Preclinical; HEK293 Cells; Humans; Microbial Sensitivity Tests; Molecular Conformation; Molecular Docking Simulation; Mycobacterium tuberculosis; Oxides; Quinoxalines; Structure-Activity Relationship; Triazoles | 2020 |
Discovery of triazoloquinoxaline as novel STING agonists via structure-based virtual screening.
Topics: Binding Sites; Cell Line, Tumor; Cell Survival; Cytokines; Drug Design; Humans; Interferon Regulatory Factor-3; Membrane Proteins; Molecular Docking Simulation; Protein Serine-Threonine Kinases; Quinoxalines; Signal Transduction; Triazoles | 2020 |
Synthesis of [1,2,4]triazolo[4,3-a]quinoxaline-1,3,4-oxadiazole derivatives as potent antiproliferative agents via a hybrid pharmacophore approach.
Topics: Antineoplastic Agents; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Oxadiazoles; Quinoxalines; Structure-Activity Relationship; Triazoles; Tumor Cells, Cultured | 2020 |
Design, synthesis, molecular docking and anti-proliferative evaluations of [1,2,4]triazolo[4,3-a]quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors.
Topics: Antineoplastic Agents; Cell Proliferation; DNA; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Intercalating Agents; Molecular Docking Simulation; Molecular Structure; Quinoxalines; Structure-Activity Relationship; Topoisomerase II Inhibitors; Triazoles; Tumor Cells, Cultured | 2020 |
Repurposing potential of posaconazole and grazoprevir as inhibitors of SARS-CoV-2 helicase.
Topics: Amides; Antiviral Agents; Carbamates; COVID-19 Drug Treatment; Cyclopropanes; Drug Repositioning; Enzyme Inhibitors; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Protein Domains; Quinoxalines; RNA Helicases; SARS-CoV-2; Sulfonamides; Triazoles; Viral Proteins | 2021 |
New bis([1,2,4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Hep G2 Cells; Humans; MCF-7 Cells; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Quinoxalines; Structure-Activity Relationship; Triazoles; Vascular Endothelial Growth Factor Receptor-2 | 2021 |
Identification of new [1,2,4]triazolo[4,3-a]quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Protein Kinase Inhibitors; Quinoxalines; Structure-Activity Relationship; Triazoles; Vascular Endothelial Growth Factor Receptor-2 | 2021 |
Targeting VEGFR-2 by new quinoxaline derivatives: Design, synthesis, antiproliferative assay, apoptosis induction, and in silico studies.
Topics: Animals; Antineoplastic Agents; Apoptosis; Computer Simulation; Female; Hep G2 Cells; Humans; Inhibitory Concentration 50; MCF-7 Cells; Mice; Quinoxalines; Rats; Sorafenib; Structure-Activity Relationship; Triazoles; Vascular Endothelial Growth Factor Receptor-2 | 2022 |